Back to search results

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Metastatic Triple-Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Clinton Yam, MD) · TNBC-NOW@mdanderson.org · 713-792-2817
    Contact: Principal Investigator (Clinton Yam, MD)
Study leads

  • Clinton Yam, MD

    Principal Investigator

    M.D. Anderson Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)